Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?

Abstract Precision medicine has provided new perspectives in oncology, yielding research on the use of targeted therapies across different tumor types, regardless of their site of origin, a concept known as tissue-agnostic indication. Since 2017, the Food and Drug Administration (FDA) has approved t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luiza N. Weis, Sara M. Tolaney, Carlos H. Barrios, Romualdo Barroso-Sousa
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/99ddf49ec2724697925a230a9dd6ae2f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:99ddf49ec2724697925a230a9dd6ae2f
record_format	dspace
spelling	oai:doaj.org-article:99ddf49ec2724697925a230a9dd6ae2f2021-12-02T17:24:12ZTissue-agnostic drug approvals: how does this apply to patients with breast cancer?10.1038/s41523-021-00328-32374-4677https://doaj.org/article/99ddf49ec2724697925a230a9dd6ae2f2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00328-3https://doaj.org/toc/2374-4677Abstract Precision medicine has provided new perspectives in oncology, yielding research on the use of targeted therapies across different tumor types, regardless of their site of origin, a concept known as tissue-agnostic indication. Since 2017, the Food and Drug Administration (FDA) has approved the use of three different agents for tumor-agnostic treatment: pembrolizumab (for patients with microsatellite instability or high tumor mutational burden) and larotrectinib and entrectinib (both for use in patients harboring tumors with NTRK fusions). Importantly, the genomic alterations targeted by these agents are uncommon or rare in breast cancer, and little information exists regarding their efficacy in advanced breast cancer. In this review, we discuss the prevalence of these targets in breast cancer, their detection methods, the clinical characteristics of patients whose tumors have these alterations, and available data regarding the efficacy of these agents in breast cancer.Luiza N. WeisSara M. TolaneyCarlos H. BarriosRomualdo Barroso-SousaNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Luiza N. Weis Sara M. Tolaney Carlos H. Barrios Romualdo Barroso-Sousa Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
description	Abstract Precision medicine has provided new perspectives in oncology, yielding research on the use of targeted therapies across different tumor types, regardless of their site of origin, a concept known as tissue-agnostic indication. Since 2017, the Food and Drug Administration (FDA) has approved the use of three different agents for tumor-agnostic treatment: pembrolizumab (for patients with microsatellite instability or high tumor mutational burden) and larotrectinib and entrectinib (both for use in patients harboring tumors with NTRK fusions). Importantly, the genomic alterations targeted by these agents are uncommon or rare in breast cancer, and little information exists regarding their efficacy in advanced breast cancer. In this review, we discuss the prevalence of these targets in breast cancer, their detection methods, the clinical characteristics of patients whose tumors have these alterations, and available data regarding the efficacy of these agents in breast cancer.
format	article
author	Luiza N. Weis Sara M. Tolaney Carlos H. Barrios Romualdo Barroso-Sousa
author_facet	Luiza N. Weis Sara M. Tolaney Carlos H. Barrios Romualdo Barroso-Sousa
author_sort	Luiza N. Weis
title	Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
title_short	Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
title_full	Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
title_fullStr	Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
title_full_unstemmed	Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
title_sort	tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/99ddf49ec2724697925a230a9dd6ae2f
work_keys_str_mv	AT luizanweis tissueagnosticdrugapprovalshowdoesthisapplytopatientswithbreastcancer AT saramtolaney tissueagnosticdrugapprovalshowdoesthisapplytopatientswithbreastcancer AT carloshbarrios tissueagnosticdrugapprovalshowdoesthisapplytopatientswithbreastcancer AT romualdobarrososousa tissueagnosticdrugapprovalshowdoesthisapplytopatientswithbreastcancer
_version_	1718380925332488192

Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?

Ejemplares similares